Stock listing

Biohaven Ltd.

Selected listing: BHVN · NYSE · USD · US

Biohaven Ltd. (NYSE:BHVN), Health Technology. Latest release Sep 28, 2026: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary…

BHVN:NYSEUSDUSUpdated September 25, 2026

Ticker: NYSE:BHVN
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: NYSE
Currency: USD

About Biohaven Ltd.

Biohaven Ltd. is a public company traded under the ticker BHVN in the American market. Biohaven focuses on developing innovative therapies for neurological diseases, aiming to improve patient outcomes.

Latest news from Biohaven Ltd.

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

September 28, 2026

Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy

August 27, 2026

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload

July 20, 2026

Biohaven Announces Scientific Leadership Transitions

July 9, 2026

Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator

June 30, 2026

All Biohaven Ltd. news →

Events

Replays

Biohaven Ltd. (BHVN) Q4 2021 Earnings Call
Fri, Feb 25, 2022 · 08:30 AM ET
Watch
Biohaven Ltd. (BHVN) Q3 2021 Earnings Call
Tue, Nov 09, 2021 · 08:00 AM ET
Watch
Biohaven Ltd. (BHVN) Q2 2021 Earnings Call
Mon, Aug 09, 2021 · 08:30 AM ET
Watch